Frankenius Equity AB
SEC CIK 1988262 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | 10% | 6.99M | $250.0K | — | 2 | 2024-12-17 | 2025-07-31 |
Most active insiders at TLSI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Stansky Michael P | Dir | $3.01M | — |
| 2 | Szela Mary T | CEO, Pres, Dir | $227.8K | $79.4K |
| 3 | Wahlstrom Mats | Dir | $151.8K | — |
| 4 | Valle William | Dir | $125.0K | — |
| 5 | Gordon Gary B. | Dir | $64.6K | — |
| 6 | Patience David | CFO | $32.2K | — |
| 7 | Marshak Richard | Chief Commercial Off | — | $15.7K |
| 8 | Stevens Jennifer | Chief Regulatory Off | — | $14.5K |
| 9 | Devlin Jodi | Chief of Clinical Ops | — | $13.2K |
| 10 | Cox Bryan F. | Chief of Research | — | $13.1K |
Frankenius Equity AB made no open-market trades at TLSI in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-20 16:36 | 2025-07-31 | TLSI | TriSalus Life Sciences, Inc. | Frankenius Equity AB | 10% | C - Cnv Deriv | $0.00 | +759.0K | 6.99M | +12% | $0 |
| 2024-12-19 | 2024-12-17 | TLSI | TriSalus Life Sciences, Inc. | Frankenius Equity AB | 10% | P - Purchase | $3.97 | +63.0K | 6.23M | +1% | +$250.0K |
Purchase Sale Sale after option exercise All abbreviations